Moderate-to-Severe Refractory Ulcerative Colitis: Focus on Tacrolimus

Kazuhiro Watanabe; Hitoshi Ogawa; Chikashi Shibata; Koh Miura; Takeshi Naitoh; Masayuki Kakyo; Makoto Kinouchi; Toshinori Ando; Nobuki Yazaki; Naoki Tanaka; Sho Haneda; Manabu Sato; Iwao Sasak

JOURNAL

Clinical Medicine Reviews in Therapeutics

Moderate-to-Severe Refractory Ulcerative Colitis: Focus on Tacrolimus

Kazuhiro Watanabe, Hitoshi Ogawa, Chikashi Shibata, Koh Miura, Takeshi Naitoh, Masayuki Kakyo, Makoto Kinouchi, Toshinori Ando, Nobuki Yazaki, Naoki Tanaka, Sho Haneda, Manabu Sato and Iwao Sasak

Clinical Medicine Reviews in Therapeutics 2010:2

Review

Published on 30 Nov 2010

DOI: 10.4137/CMRT.S3250

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract and Sharing
Article Metrics
Discuss

Abstract

Tacrolimus, a 23-member macrolide lactone discovered in 1984 from the actinomycete Streptomyces tsukubaensis, was the first macrolide immunosuppressant agent. Tacrolimus was first used for patients after liver transplantation to reduce the activity of the patient's immune system and the risk of organ rejection. Oral tacrolimus was recently approved for use in steroid-refractory moderate-to-severe ulcerative colitis in Japan. This review focuses on the clinical efficacy and safety data of tacrolimus in moderate-to-severe refractory ulcerative colitis.

Downloads

RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation (BIBDESK, LATEX)

What Your Colleagues Say About Libertas Academica

My experience with Libertas Academica was very positive from submission to acceptance. The reviewers' comments were very interesting and constructive. The author interface was user-friendly and very effective. The publishing process was fast and convenient. I recommend this journal.

Dr Marco Berlucchi (Department of Pediatric Otorhinolaryngology, Spedali Civili, Brescia, Italy)

More Testimonials